1047

EFFECT OF SCREENING STRATEGIES ON THE NATURAL HISTORY OF IBD-RELATED AND SPORADIC COLORECTAL CANCER

Date
May 21, 2024

Background: Inflammatory bowel disease encompasses two types of idiopathic intestinal disease, ulcerative colitis (UC) and Crohn's disease (CD) that are differentiated by their location and depth of involvement in the bowel wall. Both of them are risk factors for the onset of colorectal cancer (CRC) and patients should undergo a specific endoscopic surveillance program. This study aimed to assess the burden of the missed surveillance for CRC in patients with UC and CD and to identify possible factors associated with morbidity.
Methods: Records of consecutive patients who underwent surgery for UC-related and CD-related adenocarcinoma in our institution were reviewed. Cancer cases occurring in UC and in CD were compared with 324 patients who underwent curative-intent surgery for a histologically confirmed sporadic CRC and participated in a multicenter study on the effect of screening on patients' outcomes in the Veneto region. Non-parametric tests, logistic regression analysis, and survival analysis were performed.
Results: In UC and CD patients, CRC diagnosed at screening colonoscopy was more frequently stage I or II (p=0.04) and nodal metastasis over nodal harvest ratio was significantly lower (p=0.02) than cancer diagnosed in symptomatic patients. Anti-TNF-alpha therapy was associated with a significantly decreased risk of CRC (OR= 0.27 (95% CI 0.08-0.83), p=0.02). The rate of CRC occurrence confirmed a significant trend to rise according to disease duration (p<0.0001). Finally, patients with sporadic CRC or UC and CD-related CRC diagnosed at screening colonoscopy showed significantly better survival than those diagnosed because of symptoms (p=0.02).
Discussion: Our study confirmed that endoscopic surveillance is effective not only in the early detection of preneoplastic lesions/CRC in UC but also in detecting early stages of UC-related cancer. Moreover, anti-TNF-α therapy can play a role in the chemoprevention in UC. The study also confirmed that endoscopic follow-up in CD is associated with the early detection of CRC lesions and with an earlier cancer stage at diagnosis.

Tracks

Related Products

Thumbnail for IMMUNOREACT 13: IMMUNE SURVEILLANCE MARKERS IN THE CLINICAL MANAGEMENT OF STAGE II RECTAL CANCER
IMMUNOREACT 13: IMMUNE SURVEILLANCE MARKERS IN THE CLINICAL MANAGEMENT OF STAGE II RECTAL CANCER
BACKGROUND Stage II colorectal cancer should undergo adjuvant therapy only in the presence of risk factors and vascular, lymphatic, and perineural invasion (VELIPI) are risk factors for recurrence after surgery…
Thumbnail for EARLY SURGERY IN NEWLY DIAGNOSED ILEOCOLIC CROHN'S DISEASE: LONG TERM DISEASE ACTIVITY AND QUALITY OF LIFE.
EARLY SURGERY IN NEWLY DIAGNOSED ILEOCOLIC CROHN'S DISEASE: LONG TERM DISEASE ACTIVITY AND QUALITY OF LIFE.
BACKGROUND: Gastroesophageal reflux disease (GERD), with or without hiatal hernia (HH), affects millions of individuals worldwide, with a significant economic impact and loss of health-related quality of life…
Thumbnail for IMMUNOREACT 3: PERITUMORAL IMMUNE MICROENVIRONMENT MARKERS AS PREDICTORS OF RECURRENCE AFTER ADJUVANT THERAPY IN LOCALLY ADVANCED RECTAL CANCER
IMMUNOREACT 3: PERITUMORAL IMMUNE MICROENVIRONMENT MARKERS AS PREDICTORS OF RECURRENCE AFTER ADJUVANT THERAPY IN LOCALLY ADVANCED RECTAL CANCER
BACKGROUND: Adjuvant therapy after rectal cancer surgery is indicated in T4N0 or any T and nodal metastasis and/or risk factors for recurrences…
Thumbnail for IMMUNOREACT 8: IMMUNE MARKERS AS PREDICTORS OF LOCAL TUMOR SPREAD IN PATIENTS UNDERGOING TRANSANAL EXCISION FOR RECTAL CANCER
IMMUNOREACT 8: IMMUNE MARKERS AS PREDICTORS OF LOCAL TUMOR SPREAD IN PATIENTS UNDERGOING TRANSANAL EXCISION FOR RECTAL CANCER
LUNCH AND TRAINEE JEOPARDY! 12:00 PM - 1:00 PM LEADERSHIP FORUM, NETWORKING SESSION AND ROUNDTABLES 4:00 PM - 5:30 PM KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY 4:00 PM - 4:30 PM